EGFR ligands dictate tumour suppression

Nat Cell Biol. 2022 Aug;24(8):1189-1191. doi: 10.1038/s41556-022-00967-z.

Abstract

Amplification of EGFR occurs frequently in glioblastoma. Canonically, EGFR is an oncogene with a major role in cancer pathogenesis. A new study posits a tumor suppressive role of EGFR in EGFR-amplified glioblastoma, regulated by ligand abundance. Increased EGFR ligand in EGFR-amplified glioblastoma suppresses invasion by upregulation of BIN3, inhibiting activation of Rho GTPases.

Publication types

  • Comment

MeSH terms

  • Epidermal Growth Factor
  • ErbB Receptors* / genetics
  • Humans
  • Ligands
  • Neoplasms* / genetics

Substances

  • Ligands
  • Epidermal Growth Factor
  • EGFR protein, human
  • ErbB Receptors